Where is Novo Nordisk A/S (NVO) Headed?
Novo Nordisk A/S (NYSE:NVO) is one of the best affordable healthcare stocks to buy now. On December 22, Novo Nordisk A/S (NYSE:NVO) announced the FDA approval of the Wegovy® pill, a once-daily oral semaglutide 25 mg, for long term weight management, excess body weight reduction, and reduction in the risk of major adverse cardiovascular events. The approval makes […]
WEIGHTLESS
The author’s ethos throughout her discussion of GLP-1 medications is that obesity is a chronic issue that doctors treated from the wrong perspective: “For too long, we approached chronic conditions such as obesity as ‘willpower problems’ or moral failings….We treated the symptoms but did nothing to treat the disease because we didn’t fully understand it […]
Jim Cramer Discusses Molson Coors (TAP) & Alcohol Industry
We recently published 8 Stocks on Jim Cramer’s Radar. Molson Coors Beverage Company (NYSE:TAP) is one of the stocks on Jim Cramer’s radar. Molson Coors Beverage Company (NYSE:TAP) is an alcoholic beverage company. The shares are down by 18% year-to-date as the firm has struggled due to the broader weakness in the alcoholic beverage industry. […]
Jim Cramer Discusses Brown-Forman (BF-B) & Alcohol Industry
We recently published 8 Stocks on Jim Cramer’s Radar. Brown-Forman Corporation (NYSE:BF-B) is one of the stocks on Jim Cramer’s radar. Brown-Forman Corporation (NYSE:BF-B) is another alcoholic beverage firm whose shares have struggled in 2025. The stock is down by 29% year-to-date and has suffered particularly in 2025. Since December 11th, Brown-Forman Corporation (NYSE:BF-B)’s shares […]
Lupin signs exclusive licensing deal with Gan & Lee for novel GLP-1 receptor agonist
Lupin announced that it has entered into an exclusive license, supply, and distribution agreement with China-based Gan & Lee Pharmaceuticals for Bofanglutide, a novel fortnightly GLP-1 receptor agonist.
Nutrients, Vol. 18, Pages 119: Intermittent Fasting and Probiotics for Gut Microbiota Modulation in Type 2 Diabetes Mellitus: A Narrative Review
Nutrients, Vol. 18, Pages 119: Intermittent Fasting and Probiotics for Gut Microbiota Modulation in Type 2 Diabetes Mellitus: A Narrative Review Nutrients doi: 10.3390/nu18010119 Authors: Zhiwen Zhang Shaokang Wang Guiju Sun Da Pan Background: Type 2 diabetes mellitus (T2DM) is a global epidemic in which gut microbiota dysbiosis contributes to impaired glucose homeostasis and chronic […]
Lupin shares in focus after licensing pact with China’s Gan & Lee for GLP-1 drug
Lupin Ltd has secured exclusive rights in India for Bofanglutide, a novel fortnightly GLP-1 receptor agonist, through a licensing agreement with China’s Gan & Lee Pharmaceuticals. This strategic move bolsters Lupin’s diabetes and obesity treatment portfolio, offering a convenient and effective option for patients amidst a growing metabolic health challenge in India.
GLP-1 Agents Tied to Less Risk of Asthma Exacerbations in Teens With Obesity
(MedPage Today) — Adolescents with overweight or obesity and asthma had a lower risk of asthma exacerbations after starting a GLP-1 receptor agonist, a retrospective cohort study found. Among 1,070 patients ages 12 to 18, 5.4% of those taking…
STAT+: With the Wegovy pill, Novo Nordisk undercuts Eli Lilly in direct-to-consumer market
Novo Nordisk plans to sell its newly approved obesity pill directly to patients at a lower price than a competing medicine from Eli Lilly, as the Danish drugmaker tries to seize market share among consumers paying cash for blockbuster GLP-1 therapies. Novo will sell the highest doses of its Wegovy pill, cleared last week, at […]
Amanda Bynes Opens Up About Using Injections After Paparazzi Pic Shows Dramatic Weight Loss
Amanda Bynes has offered a candid update on her ongoing weight loss journey. On December 22, the former Nickelodeon star reposted a viral paparazzi photo to her Instagram Story, revealing that she had lost nearly 30 pounds since starting GLP-1 medication. The snapshot, taken during a casual outing in Los Angeles, showed Bynes walking down […]